← Back
Data updated: Jun 28, 2026
PRAXAIR MEXICO
Pharma Pharmaceuticals
PRAXAIR MEXICO is a pharmaceutical company with 1 FDA-approved products.
2017
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules
PRAXAIR MEXICO's Key Drugs
PRAXAIR MEXICO's core commercial portfolio centers on OXYGEN, USP — its most strategically important drugs approved in the last 15 years.
PRAXAIR MEXICO's Recent FDA Approvals
New NDA/BLA approvals for PRAXAIR MEXICO over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
PRAXAIR MEXICO's Therapeutic Areas
Disease areas where PRAXAIR MEXICO has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
PRAXAIR MEXICO Pipeline Snapshot
Active clinical trials for PRAXAIR MEXICO across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • OXYGEN, USP leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2017-09-03
- Latest
- 2017-09-03
- Applications
- 1